Navigation Links
Astellas Highlights Progress to Advance Care of Patients with Genitourinary Cancers at ASCO-GU Annual Meeting
Date:2/13/2013

NORTHBROOK, Ill., Feb. 13, 2013 /PRNewswire/ -- Astellas Pharma US, Inc., a U.S. subsidiary of Tokyo-based Astellas Pharma Inc. (Tokyo: 4503), today announced that more than 10 abstracts from Astellas oncology pipeline agents and marketed products will be presented at the 2013 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO-GU), to be held February 14-16 in Orlando, Florida.

"We're committed to delivering new treatment options for patients with GU cancers," said Mark Reisenauer , vice president, Astellas Oncology. "The data to be presented at ASCO GU further illustrates the potential role our products can play."

Key presentations to be made at ASCO-GU include:

Enzalutamide

Data from a 25-week, open label, single-arm phase 2 study highlighting the effect of enzalutamide on prostate-specific antigen (PSA) response in men with hormone-naive prostate cancer will be presented. Five additional abstracts will highlight outcomes from a phase 1 study of enzalutamide in combination with docetaxel chemotherapy, as well as additional findings from the randomized, global, placebo-controlled phase 3 AFFIRM study of enzalutamide in men with metastatic castration resistant prostate cancer. XTANDI was approved by the FDA on August 31, 2012 for the treatment of patients with metastatic castration-resistant prostate cancer who have previously received docetaxel (chemotherapy). A Marketing Authorization Application for XTANDI is currently under review by the European Medicines Agency (EMA).

Tivozanib

Additional secondary analysis results from the Phase 3 TIVO-1 (tivozanib versus sorafenib in 1st line advanced RCC) trial will be presented.  Reported data will include overall survival (OS) results for metastatic renal cell carcinoma (mRCC) patients who received ti
'/>"/>

SOURCE Astellas Pharma US, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Ambit and Astellas Announce Presentation of Results from Phase 2 ACE Study of Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) at the 54th Annual Meeting of the American Society of Hematology
2. Astellas Announces Acceptance of U.S. New Drug Application for Tacrolimus Extended Release Capsules
3. Personal Connections Drive Employee Participation For Changing Tomorrow Day at Astellas
4. Astellas to Close Urogenix, North Carolina-based Urology Research Facility
5. Astellas and Fujita Health University Discover Neuronal Maturation Deficits in Patients Suffering from Schizophrenia and Bipolar Disorder
6. First sales of DIFICLIR™ by Astellas Pharma Europe triggers 10 Million Euro Milestone Payment to Optimer Pharmaceuticals
7. CTIA-The Wireless Association Highlights Connected Health Benefits and Potential
8. Zacks Bull and Bear of the Day Highlights: Smithfield Foods, Logitech International, Sanofi, Isis Pharmaceuticals and Aegerion Pharmaceuticals
9. Philips Highlights Future Innovations at RSNA 2012 Transformation Lab
10. Novartis highlights key data in patients with hematologic diseases and breast cancer with more than 140 abstracts at ASH and SABCS
11. CLAAD Highlights 5 Technologies To Reduce Prescription Drug Abuse
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... 16, 2014 Astellas announced today it ... Communications & Advocacy, Urology in the Americas. Noland will ... Advocacy Margaret Long. In this role, Noland will be ... patient and advocacy organizations, as well as collaborating ... initiatives. Noland,s appointment is the latest phase in ...
(Date:9/16/2014)... 2014 /PRNewswire-iReach/ -- Dan York has been ... of the RTD ® Advanced Wound Care Dressing, ... sales presence in the U.S. Under York,s leadership, GWM ... field sales representatives in new sales territories that will ... add up to 20 sales representatives in major metropolitan ...
(Date:9/16/2014)... DIEGO , Sept. 16, 2014  Denovo ... enzastaurin, a late-stage oncology drug, from Eli Lilly ... to develop, manufacture and commercialize enzastaurin globally, including ... data, and information. Lilly developed ... Phase 2 and Phase 3 clinical trials for ...
Breaking Medicine Technology:Christy Noland to Lead Urology Advocacy and Communications for Astellas 2GWM Products, LLC, announces U.S. market expansion. Dan York added as Director of Sales as part of nationwide growth initiative. 2Denovo Biopharma Acquires Late-Stage Oncology Drug From lilly For Development As A Personalized Medicine 2
... 2011 Reportlinker.com announces that a new market research ... Gastric Cancer Drug Discoveries: what the future holds ... Original analysis of the clinical potential ... candidates put into current market context Original ...
... 2011 Reportlinker.com announces that a new market research report ... Stent Market Outlook to 2016 http://www.reportlinker.com/p0483600/The-Drug-Eluting-Stent-Market-Outlook-to-2016.html ... DES market has seen tremendous growth since the introduction of ... on the release of clinical data that indicated a link ...
Cached Medicine Technology:Reportlinker Adds Gastric Cancer Drug Discoveries: what the future holds 2Reportlinker Adds Gastric Cancer Drug Discoveries: what the future holds 3Reportlinker Adds Gastric Cancer Drug Discoveries: what the future holds 4Reportlinker Adds Gastric Cancer Drug Discoveries: what the future holds 5Reportlinker Adds the Drug-Eluting Stent Market Outlook to 2016 2Reportlinker Adds the Drug-Eluting Stent Market Outlook to 2016 3Reportlinker Adds the Drug-Eluting Stent Market Outlook to 2016 4
(Date:9/16/2014)... 2014 Keep that sexy decolletage as you ... neck. , "The Face Whisperer Neck & Decollete Cream ... Heshelow, founder of Sublime Beauty®. "It contains rich ingredients to ... and arnica." , A special ingredient is Argireline, known as ... rich anti-aging cream comes in an airless pump bottle, and ...
(Date:9/16/2014)... (PRWEB) September 16, 2014 Today, ... published new information on transitioning employees to individual ... with the Affordable Care Act (ACA) in full ... be steering some or all of their employees ... surprise. With guaranteed issue plans, coverage for pre-existing ...
(Date:9/16/2014)... the well-known wedding dress manufacturer and retailer, has unveiled ... Additionally, the firm has launched a promotion for its ... up to 62 percent off. , All ... won a lot of positive reviews for its high-quality ... big savings on many other items, including corset bridesmaid ...
(Date:9/16/2014)... 16th, 2014; San Francisco) In a healthcare ... weighed against potential benefit, a Yale study has ... less-aggressive radiation procedures on elderly women with early-stage ... presented at the 56th annual conference of the ... (Abstract 131: Evaluating National Practice in Radiotherapy for ...
(Date:9/16/2014)... Recently, iFitDress.com, one of the most famous dress suppliers ... evening gown collection. According to the company’s sales manager, ... (up to 69% off) at present. Additionally, all the company’s ... am a frequent caller of your site. I like your ... feel quite happy. All items are of good quality. I ...
Breaking Medicine News(10 mins):Health News:15% Off Face Whisperer® Neck & Decollete Cream Now from Sublime Beauty; Care For This Delicate Skin That Shows Age Quickly 2Health News:Zane Benefits Publishes New Information on Transitioning Employees to Individual Health Insurance 2Health News:New Elegant Evening Wear Assortment Released By UWDress.com 2Health News:iFitDress.com: One Shoulder Evening Gown Collection Unveiled Online 2
... a 60-cm-long sword that had been thrust through the nose ... ear, news reports said Wednesday. ,Ronnachai Tiemsanguan, 16, ... sword's removal from his face in an operation that took ... newspaper. ,Ronnachai received his sword wound Saturday when ...
... in the field of conducting tasks that involve spatial ... light turns green. , Researcher Eric Schumacher, ... Technology and colleagues, were surprised when they conducted MRI ... ,The researchers were testing the notion that areas ...
... suggests that ovarian cancer cells form by hijacking a ... Scientists at the Georgia Institute of Technology and the ... involved in the development of fallopian tubes and is ... ovarian tissue. The discovery not only provides a new ...
... Barbara, California – March 6, 2007 -- A team ... Berkeley and StrataGent// Life Sciences, of Los Gatos, California, ... to deliver protein drugs into the skin without the ... The research was published online today in the Proceedings ...
... It's already been established that type 2 diabetes increases the ... also a link between type 1 diabetes and this type ... but still, those with type 1 diabetes have a likelihood ... in non-diabetics. This is similar to the risk those with ...
... International Narcotics Control Board (INCB) – an independent body ... control// standards – is calling for the danger of ... ,In its annual report, the Vienna-based organisation ... drugs are not illegally manufactured or diverted from authorised ...
Cached Medicine News:Health News:Same Areas of the Brain Prepare for and Respond to a Stimulus, Say Experts 2Health News:Ovarian Cancer May Mimic Fallopian Tube Formation 2Health News:Ovarian Cancer May Mimic Fallopian Tube Formation 3Health News:Researchers Design Pulsed Mircrojet System to Deliver Protein Drugs Without Pain or Bruising 2Health News:Flood of Fake Drugs Must Be Stopped, Warns UN 2
... The RapidPCP test is an immunochromatography ... It is,designed for qualitative determination of ... cut-off level of 25 ng/mL. This ... the point of care location,and is ...
... Rapid Opiate II Rapid Opiates is an ... is designed for qualitative determination of Opiates ... presence of morphine in human urine above ... This assay has not been evaluated in ...
... All of DOA Panel ... one step in vitro test. ... of drug substances in human ... not,been evaluated in the point ...
... an immunochromatography based one step in vitro ... THC and its metabolites in human urine,specimens. ... urine above a cut-off,level of 50 ng/mL ... been evaluated in the point of care,location ...
Medicine Products: